Trial reportJAMA1987
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Trial report in JAMA, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT00000599. Cited by 208 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cholesterol-Lowering Atherosclerosis Study (CLAS)
Lipoprotein Metabolism in Normal Volunteers and Dyslipoproteinemic Patients (Stable Isotopes)
Who cites it
208 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,643 citations in OpenAlex.
- The association between coronary graft patency and clinical status in patients with coronary artery disease.European heart journal · 2021Pooled it
- Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.JAMA network open · 2019 · on this mapPooled it
- Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.European journal of preventive cardiology · 2019 · on this mapPooled it
- Niacin for primary and secondary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2017 · on this mapPooled it
- Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.Heart (British Cardiac Society) · 2016 · on this mapPooled it
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.BMJ (Clinical research ed.) · 2014Pooled it
- Lipid-lowering for peripheral arterial disease of the lower limb.The Cochrane database of systematic reviews · 2007Pooled it
- Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.Heart (British Cardiac Society) · 1998Guideline
- Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.Annals of surgery · 1996Pooled it
- By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?BMJ (Clinical research ed.) · 1994Pooled it
- Cholesterol lowering and mortality: the importance of considering initial level of risk.BMJ (Clinical research ed.) · 1993Pooled it
- Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.Postgraduate medical journal · 1993Guideline
- Guidelines for the management of hyperlipidaemia in general practice. Towards the primary prevention of coronary heart disease. Royal College of General Practitioners.Occasional paper (Royal College of General Practitioners) · 1992Guideline
- Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2018 · on this mapTrial
- Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial.The American journal of clinical nutrition · 2008Trial
- Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.Clinical cardiology · 2001Trial
- Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.Cardiovascular drugs and therapy · 1995Trial
- Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study.International journal of cardiac imaging · 1994Trial
- The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study.The Clinical investigator · 1994Trial
- Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins.The Clinical investigator · 1994Trial
148 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% reduction in total plasma cholesterol, a 43% reduction in low-density lipoprotein cholesterol, plus a simultaneous 37% elevation of high-density lipoprotein cholesterol. This resulted in a significant reduction in the average number of lesions per subject that progressed (P less than .03) and the percentage of subjects with new atheroma formation (P less than .03) in native coronary arteries. Also, the percentage of subjects with new lesions (P less than .04) or any adverse change in bypass grafts (P less than .03) was significantly reduced. Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects (P less than .001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (P = .002).
Indexed as
Identifiers
3295315W2145799136What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.